We read thirty-seven ED product pages. Seventeen never mention the interaction that can kill you.

What we did

Thirty-one services: compounded combination products, plain FDA-approved generics, telehealth marketplaces, a prescribing platform, a clinic offering injectable therapy, and two compounding pharmacies. For each one we read the public page — the page an advert sends you to — and recorded whether seven specific pieces of information were present before the point of purchase.

We did not test the products and we did not complete the intake questionnaires: doing that means submitting real medical details and paying. So this is an audit of what a man is told before he decides, which is narrower than whether each company practises good medicine. It is also the question that determines whether he knows enough to decide safely.

One caveat we discovered the hard way: a company may run several landing pages for the same product, and they do not always disclose the same things. Where that happened we scored the page its paid advertising points to, and said so. Every individual assessment names the exact page and the date we read it — they are all on our reviews page.

The results

Two rows carry a couple of “not applicable” results, excluded from the counts above: a service selling only FDA-approved generics has no compounding disclosure to make, and a pharmacy filling a prescription has no subscription to cancel.

The bottom rows are ordinary consumer-transparency failures. The top three are the ones that can put someone in hospital.

Why the nitrate row is the one that matters

Nitrates are common heart medicines: nitroglycerin tablets and spray, isosorbide mononitrate and dinitrate, and the recreational amyl nitrite sold as “poppers”. They widen blood vessels. So do all the drugs in these products.

Taken together, blood pressure can fall far enough to starve the heart and brain. People have died from this combination. It is not a caution to weigh against benefits — it is an absolute contraindication, printed on the label of every approved drug in this class.

Now consider who buys these products. Men in their fifties and sixties. The same men most likely to be carrying a nitroglycerin spray for angina. The overlap between the target market and the contraindicated group is enormous, and half the pages we read say nothing.

One page told us its product can cause low blood pressure, and never once connected that to the drug interaction which makes low blood pressure dangerous.

The ones that got it right

Fifteen of thirty-seven do this properly, and the best of them do the thing that actually changes behaviour — they explain the consequence rather than just naming the drug class:

“Do NOT take any... products if you take medication containing nitrates or guanylate cyclase stimulators for pulmonary hypertension, as this could cause an unsafe drop in blood pressure.”

Others go further. One names poppers by their actual chemistry — amyl nitrate, amyl nitrite, butyl nitrate — rather than assuming a reader connects the slang to the drug class. One names riociguat and alpha-blockers specifically. One lists the consequences as “fainting, heart attack, or stroke”. A compounding pharmacy states it as a flat contraindication alongside a systolic blood pressure threshold of 90 mmHg.

Three more mention nitrates without explaining anything — “should not be taken with nitrates or certain other medications”, with no brand names and no consequence. We scored those partial, because a warning that does not tell you what is at stake mostly does not work on the man carrying a spray he does not think of as a nitrate.

All of this is standard label information. It has been available to every company in this comparison the entire time.

The dose problem

Twenty of the thirty-seven publish no doses at all. They name the ingredients and leave the quantities out.

That is not a transparency quibble, for two reasons. First, a great many men over 50 already have generic sildenafil or tadalafil in a drawer — and without a dose there is no way to know whether taking both would double up. Second, among the pages that do publish doses, the range is enormous:

The bottom two rows exceed approved maximums. The pharmacy one is defensible — a prescriber who has examined you chooses it, which is the whole point of compounding. The consumer product tier that exceeds the maximum of *both* drugs, sold off a questionnaire, is a different proposition.

If products span that range and more than half will not say where they sit, “compounded ED treatment” is not a meaningful description of what you are buying.

What “compounded” means, and who says it

There is no FDA-approved medicine that combines two PDE5 inhibitors. So every combination product in this audit is compounded — mixed to order by a pharmacy rather than manufactured and approved as a product.

Compounding is legal and legitimate. But it carries a consequence, which most of these services now state plainly: the FDA has not assessed the thing you are swallowing for safety, effectiveness or quality. No trial established that the combination beats one drug alone. No regulator confirmed the tablet contains what the label says.

Three pages never mention it. One of those leans on the phrase “Rx only” instead — true, and to most readers it sounds like reassurance, because prescription medicines are normally the approved ones. Another sells a “dual-ingredient dissolvable tablet” without naming either ingredient. A third carries the *dietary supplement* disclaimer, which is the wrong instrument for a prescription drug entirely.

One company, two pages, two different stories

The most instructive thing we found was not a failure but an inconsistency. One company runs two landing pages for the same product. One of them carries a full Important Safety Information block — nitrates with the mechanism explained, alpha-blockers, the four-hour rule, sudden vision and hearing loss. The other carries none of it, and uses the dietary-supplement disclaimer instead of the compounded-drug one.

Which one you see depends on which advert you click.

We scored the page the paid advertising points to, and corrected our review when we found it — the audit more than doubled. But it tells you something about how this copy gets written. The good version exists. It is a template someone already wrote. When it is missing from a page, that is a choice about conversion, not a gap in anyone's knowledge.

The pattern nobody advertises

Here is what surprised us most. The services that disclose best are, with few exceptions, the ones selling plain FDA-approved generics — not the compounded combinations sold on strength claims.

The two highest-scoring services in our comparison both sell ordinary sildenafil and tadalafil. One prints the entire label: nitrates, poppers, riociguat, the four-hour rule, NAION, sudden hearing loss, a full cardiac history prompt. The other goes further and refuses to treat you if you take nitrates or have heart disease, asks for a recent blood pressure reading, and publishes every strength of every drug it offers.

Both charge around $2 a dose. Several compounded competitors charge $114 a month, and one works out at roughly $25 a dose.

The inference is uncomfortable but hard to avoid: the more a product depends on a claim the evidence does not support, the less its page tends to tell you. Why stacking two of these drugs is not twice as good.

What to do with this

If you are buying any of these, the page may not tell you what follows. So:

1. If you take nitrates in any form, do not take any of these products. Not a lower dose, not occasionally. Tell your own doctor what you are considering.
2. Learn the washout period. After sildenafil, wait at least 24 hours before a nitrate; after tadalafil, at least 48. Combination products contain tadalafil, so the 48-hour rule governs — even though the effect wears off in a few hours and you will feel completely normal long before you are safe. On a *daily* tadalafil product there is no safe window at all. Which medicines count as nitrates.
3. An erection lasting more than four hours is an emergency room visit. Not something to wait out overnight. After roughly four to six hours the tissue starts to be damaged permanently.
4. Ask for the dose in writing before you pay. If a service will not tell you, that is your answer.
5. Put it in your medical record. A compounded product bought online will not appear there unless you tell someone. The clinician treating your chest pain in three years needs to know.

A fair word for these companies

Many of them do real things well. Most require a licensed clinician to review the case. One runs a 50-biomarker blood panel before prescribing. One requires a live consultation in some states. One publishes its street address, its state board licensure and its NCPDP number, so you can verify it in two minutes. One makes refills opt-in rather than automatic. One accepts insurance. One states openly that the high-quality trial evidence for its own product is limited.

The failure is specific and widely shared: the marketing page is written to sell, and the safety information is left to a link, a leaflet, or the intake form. That is legally orthodox and practically useless, because the decision gets made on the page.

It would take one paragraph to fix, and six of these companies have already written it. The rest are welcome to borrow it.